logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 19 of 19 Items
Showing 1 - 19 of 19 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (19)
  • CSV
  • BibTeX
  • EndNote
  • All Results (19)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

Singh-Phulgenda S, Dahal P, Maguire BJ, Alvar J, Alves F,  et al.
2025-12-02 • Parasites and Vectors
2025-12-02 • Parasites and Vectors

BACKGROUND

Visceral leishmaniasis (VL) is one of the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO). The disease is currently ...

Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Kala-azar elimination in India: Reflections on success and sustainability

Pandey DK, Alvar J, den Boer M, Jain S, Gill N,  et al.
2025-03-03 • International Health
2025-03-03 • International Health

The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the thresho...

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...

Host preference and human blood index of Phlebotomus orientalis, an exophilic sand fly vector of visceral leishmaniasis in eastern Sudan

Jibreel T, Khogali A, Jiménez M, Raiyed A, Dakein O,  et al.
2023-08-04 • Medical and Veterinary Entomology
2023-08-04 • Medical and Veterinary Entomology
Visceral leishmaniasis (VL, kala azar), caused by Leishmania donovani, transmitted by Phlebotomus orientalis, is a serious systemic disease that causes high morbidity and mortality rates...

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023

Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial

Solomos A, Musa AM, Mbui J, Mohammed R, Olobo J,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The parasitic disease visceral leishmaniasis (VL) is most commonly caused by Leishmania donovani in eastern Africa, currently the region with highest burden worldwide. C...

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS,  et al.
2018-10-22 • PLOS Neglected Tropical Diseases
2018-10-22 • PLOS Neglected Tropical Diseases
BACKGROUND
In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...

Kala-azar outbreak in Libo Kemkem, Ethiopia: epidemiologic and parasitologic assessment

Alvar J, Bashaye S, Argaw D, Cruz I, Aparicio P,  et al.
2007-08-01 • American Journal of Tropical Medicine and Hygiene
2007-08-01 • American Journal of Tropical Medicine and Hygiene
In May 2005, visceral leishmaniasis (VL) was recognized for the first time in Libo Kemkem, Ethiopia. In October 2005, a rapid assessment was conducted using data from 492 patients with V...

Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study

Coulborn RM, Gebrehiwot TG, Schneider M, Gerstl S, Adera C,  et al.
2018-11-08 • PLOS Neglected Tropical Diseases
2018-11-08 • PLOS Neglected Tropical Diseases
Ethiopia bears a high burden of visceral leishmaniasis (VL). Early access to VL diagnosis and care improves clinical prognosis and reduces transmission from infected humans; however, sig...

Towards the elimination of visceral leishmaniasis as a public health problem in East Africa: reflections on an enhanced control strategy and a call for action

Alvar J, den Boer ML, Dagne DA
2021-12-01 • Lancet Global Health
2021-12-01 • Lancet Global Health
East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only sli...

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...

Developments in the treatment of visceral leishmaniasis

den Boer ML, Alvar J, Davidson RN, Ritmeijer KKD, Balasegaram M
2009-08-27 • Expert Opinion on Emerging Drugs
2009-08-27 • Expert Opinion on Emerging Drugs
BACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontine...

Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial

Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer KKD,  et al.
2022-09-27 • Clinical Infectious Diseases
2022-09-27 • Clinical Infectious Diseases
BACKGROUND
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visce...

Control of visceral leishmaniasis in East Africa: fragile progress, new threats

Dahl EH, Hamdan M, Mabrouk L, Matendechero S, Mengistie TB,  et al.
2021-08-13 • BMJ Global Health
2021-08-13 • BMJ Global Health
SUMMARY BOX

• Significant progress has been made in reducing the global burden of visceral leishmaniasis, but new threats are on the horizon.
• Funding for elimination of ...

Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India

Goyal V, Burza S, Pandey K, Singh SN, Singh RS,  et al.
2019-09-26 • PLOS Neglected Tropical Diseases
2019-09-26 • PLOS Neglected Tropical Diseases
BACKGROUND:
An earlier open label, prospective, non-randomized, non-comparative, multi-centric study conducted within public health facilities in Bihar, India (CTRI/2012/08/002891) ...

Outdoor Residual Insecticide Spraying (ODRS), a new approach for the control of the exophilic vectors of human Visceral Leishmaniasis: Phlebotomus orientalis in East Africa

Elnaiem DA, Dakein O, Alawad AM, Alsharif B, Khogali A,  et al.
2020-10-20 • PLOS Neglected Tropical Diseases
2020-10-20 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL) due to Leishmania donovani is a neglected protozoan parasitic disease in humans, which is usually fatal if untreated. Phlebotomus orientalis, the predominant ...

Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in Eastern Africa: results from a pharmacovigilance programme

Kimutai R, Musa AM, Njoroge SM, Omollo R, Alves F,  et al.
2017-03-01 • Clinical Drug Investigation
2017-03-01 • Clinical Drug Investigation
INTRODUCTION
In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscu...

Natural history of a visceral leishmaniasis outbreak in highland Ethiopia

Herrero M, Orfanos G, Argaw D, Mulugeta A, Aparicio P,  et al.
2009-09-01 • American Journal of Tropical Medicine and Hygiene
2009-09-01 • American Journal of Tropical Medicine and Hygiene
In May 2005, visceral leishmaniasis (VL) was recognized for the first time in Libo Kemken, Ethiopia, a highland region where only few cases had been reported before. We analyzed records ...